UY25144A1 - Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h -indol - Google Patents

Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h -indol

Info

Publication number
UY25144A1
UY25144A1 UY25144A UY25144A UY25144A1 UY 25144 A1 UY25144 A1 UY 25144A1 UY 25144 A UY25144 A UY 25144A UY 25144 A UY25144 A UY 25144A UY 25144 A1 UY25144 A1 UY 25144A1
Authority
UY
Uruguay
Prior art keywords
alkyl
trifluoromethyl
dopamine
piperazin
mammal
Prior art date
Application number
UY25144A
Other languages
English (en)
Inventor
Hans Rollema
Stevin Howard Zorn
Patricia Ann Seymour
Mark Jerome Majechrzak
Anton Franz Josef Fliri
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY25144A1 publication Critical patent/UY25144A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se trata de compuestos de fórmula l (como por ejemplo: 2-[4-(3-trifluorometil-fenil)-piperazin-1-ilmetil]-1H-indol) o la sal farmacéuticamente aceptable del mismo, donde la lines discontinua representa un doble enlace opcional; a es 0 ó 1 cuando a es 0, X puede formar un doble enlace opcional con el carbono adyacente a V; T es N ó CH; V es CHR10; X es N o CR11; Y, Z pueden ser N ó CR12;. R1 es H, F, Cl, Br, trifluorometilo, trifluorometoxi, CN, o alquilo; R2, R6, R7, R8 y R9 están cada uno de ellos seleccionados entre H, F, Cl, CN, alquilo ó alcoxilo; R3 y R4 significan H ó alquilo y R5 es H, alcoxi, trifluorometilo, CN, alquilo o R13CO. Un procedimiento para tratar un trastorno del sistema de dopamina en un mamifero,el cual incluye trastornos psicóticos, del movimiento, gastrointestinales, abuso de sustancias químicas, trastornos vasculares y cardiovasculares, oculares y del sueno, que comprende la administración a dicho mamifero de un cantidad de un compuesto selectivo del receptor D4 de dopamina o una sal farmacéuticamente aceptable del mismo, junto con uno o más agonistas del receptor D1, D3, o D5 de la dopamina, que es eficaz para dicho trastorno.
UY25144A 1997-08-15 1998-08-17 Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h -indol UY25144A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5576497P 1997-08-15 1997-08-15

Publications (1)

Publication Number Publication Date
UY25144A1 true UY25144A1 (es) 2000-12-29

Family

ID=22000003

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25144A UY25144A1 (es) 1997-08-15 1998-08-17 Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h -indol

Country Status (30)

Country Link
EP (1) EP1003739A2 (es)
JP (1) JP2002536291A (es)
KR (1) KR20010022507A (es)
CN (1) CN1265660A (es)
AP (1) AP9801321A0 (es)
AR (1) AR017019A1 (es)
AU (1) AU8457298A (es)
BG (1) BG104069A (es)
BR (1) BR9811557A (es)
CA (1) CA2297486C (es)
CO (1) CO4960656A1 (es)
DZ (1) DZ2583A1 (es)
EA (1) EA200000023A1 (es)
HR (1) HRP980441A2 (es)
HU (1) HUP0003425A3 (es)
ID (1) ID23803A (es)
IL (1) IL133960A0 (es)
IS (1) IS5336A (es)
MA (1) MA24632A1 (es)
NO (1) NO20000722D0 (es)
OA (1) OA11286A (es)
PA (1) PA8457001A1 (es)
PE (1) PE106299A1 (es)
PL (1) PL338947A1 (es)
SK (1) SK1352000A3 (es)
TN (1) TNSN98151A1 (es)
TR (1) TR200000414T2 (es)
UY (1) UY25144A1 (es)
WO (1) WO1999009025A2 (es)
ZA (1) ZA987304B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2205179C2 (ru) * 1997-10-27 2003-05-27 НьюроСёрч А/С Производное гомопиперазина и фармацевтическая композиция
EP0953567A3 (en) * 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
CA2395869C (en) 1999-12-30 2006-07-25 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
GB0017952D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of dyskinesia
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
UA79309C2 (en) 2002-09-06 2007-06-11 Janssen Pharmaceutica Nv Heterocyclic compounds
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
AU2008240728B2 (en) 2007-04-23 2013-01-10 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
KR101506156B1 (ko) 2007-04-23 2015-03-26 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 티아(디아)졸
BRPI0915834A2 (pt) 2008-07-03 2015-11-03 Janssen Pharmaceutica Nv 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6
DK2307374T3 (en) 2008-07-31 2017-05-01 Janssen Pharmaceutica Nv PIPERAZIN-1-YLTRIFLUORMETHYL-SUBSTITUTED PYRIDINES AS QUICK DISSOCATING DOPAMIN-2 RECEPTOR ANTAGONISTS
JP7548814B2 (ja) * 2017-09-20 2024-09-10 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ido阻害剤および/またはido-hdac二重阻害剤としての多環式化合物
WO2021216665A1 (en) * 2020-04-22 2021-10-28 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (es) * 1959-09-25 1900-01-01
AU653855B2 (en) * 1991-07-03 1994-10-13 Pharmacia & Upjohn Company Indolyl carbonyl pyridinyl-poperazine/piperidine derivatives
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
CA2146018A1 (en) * 1992-10-23 1994-05-11 Paul David Leeson Dopamine receptor subtype ligands
WO1994021627A1 (en) * 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
WO1994024105A1 (en) * 1993-04-15 1994-10-27 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
DE4414113A1 (de) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
KR20010022507A (ko) 2001-03-15
CA2297486A1 (en) 1999-02-25
IS5336A (is) 2000-01-11
PA8457001A1 (es) 2000-09-29
CO4960656A1 (es) 2000-09-25
AP9801321A0 (en) 2000-02-14
JP2002536291A (ja) 2002-10-29
BG104069A (en) 2001-05-31
HRP980441A2 (en) 1999-04-30
WO1999009025A3 (en) 1999-04-15
ID23803A (id) 2000-05-11
ZA987304B (en) 2000-02-14
IL133960A0 (en) 2001-04-30
NO20000722L (no) 2000-02-14
NO20000722D0 (no) 2000-02-14
CN1265660A (zh) 2000-09-06
MA24632A1 (fr) 1999-04-01
SK1352000A3 (en) 2000-08-14
WO1999009025A2 (en) 1999-02-25
EA200000023A1 (ru) 2000-08-28
HUP0003425A2 (hu) 2001-10-28
TNSN98151A1 (fr) 2005-03-15
HUP0003425A3 (en) 2002-02-28
CA2297486C (en) 2005-05-03
OA11286A (en) 2003-10-22
AU8457298A (en) 1999-03-08
TR200000414T2 (tr) 2000-08-21
PE106299A1 (es) 1999-11-02
AR017019A1 (es) 2001-08-22
PL338947A1 (en) 2000-12-04
EP1003739A2 (en) 2000-05-31
DZ2583A1 (fr) 2003-02-22
BR9811557A (pt) 2000-08-22

Similar Documents

Publication Publication Date Title
UY25144A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h -indol
CO5060482A1 (es) Derivados terapeuticos de biarilo
AR034405A1 (es) Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacion
AR054799A1 (es) Derivados de oxindol
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
CO5150230A1 (es) Derivados de azetidina, su preparacion y los medicamentos que los contienen
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20021002A1 (es) Compuestos heterociclicos condensados
AR049551A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa
PE20070545A1 (es) Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo como agentes moduladores de ppar, composiciones farmaceuticas que los contienen y procedimientos para su preparacion
PE20091175A1 (es) Derivados bis-(sulfonilamino) en terapia 205
AR064049A1 (es) Derivados de acidos carboxilicos unidos a heterociclos, composiciones farmaceuticas que los contienen, y usos como promotores de la secrecion de insulina en el tratamiento de la diabetes mellitus.
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
DE60129712D1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
CO6220853A2 (es) Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios
AR063529A1 (es) Compuestos de pirazolina
PE20090757A1 (es) Formulaciones que contienen triazinonas y hierro
AR065850A1 (es) Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph
UY25986A1 (es) Complejo del inhibidor de ras-farnesiltransferasa y sulfobutiléter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y método.
PE20060323A1 (es) Oxadiazolonas y procedimientos para su preparacion
DE3868301D1 (de) 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20121130